We are neuroimaging experts for CNS clinical trials, including Alzheimer’s disease, Parkinson’s disease and Huntington's disease. Since 2004, we have analyzed over 100,000 MRI and PET brain scans from CNS trials and accredited over 2,000 imaging sites around the world.
What makes IXICO unique is our focus on data-driven AI.
We work closely with international commercial, clinical and academic partners to ensure we remain at the forefront of the clinical research industry in developing and validating unique, novel neuroimaging methods and image analysis techniques. Our goal is to provide ever more accurate and richer brain structural and functional information to further research into therapies for neurodegenerative diseases.
We provide centralized neuroradiological reading of MRI scans to assess participant eligibility and monitor drug safety. Our TrialTracker reading platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT and PET scans.
We are a recognized leader in volumetric MRI analysis. Our patented LEAP technology has been applied to thousands of datasets and provides accurate delineation of relevant brain structures while quantifying the volume of up to 137 structures in a single workflow.
We provide fully automated SUVR (Standardized Uptake Value Ratio) and dynamic analysis methods for the quantification of amyloid pathology from PET imaging. Additionally, our tau PET analysis allows us to quantify NFT distribution in different clinical groups, or monitor longitudinal changes.
Advanced MRI techniques are increasingly leveraged in CNS clinical trials to understand mechanisms that underlie many neurological disorders. IXICO's advanced MRI solutions include diffusion MRI such as diffusion tensor imaging (DTI), arterial spin labeling (ASL) and functional MRI (fMRI).